Table 2.

Univariate Cox regression analysis of survival outcomes in patients with gastric cancer

Variable	OR	95% CI	p-value
Age (years ≥ 50)	1.662	0.739–3.739	0.662
Sex (male)	1.796	0.885–3.644	0.105
ECOG PS (≥ 2)	1.049	0.565–1.947	0.880
CEA ≥ 5 (ng/ml)	1.619	0.817–3.209	0.168
CA 19–9 ≥ 37(ng/ml)	1.276	0.643–2.531	0.486
LAR ≥ 5.5	1.427	0.740–2.752	0.288
NLR ≥ 2.25	1.831	1.006–3.333	0.048
PLR ≥ 134.09	1.798	0.977–3.306	0.059
Surgical approach (TG)	1.803	0.988–3.291	0.055
Anastomotic leak	1.212	0.433–3.395	0.714
T status (T3–4)	4.059	1.255–13.131	0.019
Lymph node status (N2–3)	3.134	1.606–6.116	0.001
Metastatic-to-total harvested lymph nodes ratio (%) 1–20 20–50 ≥ 51	2.437 4.774 8.051	0.846–7.017 1.728–13.190 2.836–22.852	0.099 0.003 < 0.001
LVI	4.148	1.747–9.852	0.001
Differentiation (poor-signet ring cell)	1.328	0.726–2.430	0.357
Adjuvant therapy	1.946	0.696–5.441	0.205

OR – odds ratio, CI – confidence interval, ECOG PS – Eastern Clinical Oncology Group performance status, CEA – carcinoembryonic antigen, CA 19–9 – carbohydrate antigen 19–9, LAR – lactic dehydrogenase-to-albumin ratio, NLR – neutrophil-to-lymphocyte ratio, PLR – platelet-to-lymphocyte ratio, TG – total gastrectomy, LVI – lymphovascular invasion